Tags

Type your tag names separated by a space and hit enter

Evaluation of recombinant allergens Bet v 1 and Bet v 2 (profilin) by Pharmacia CAP system in patients with pollen-related allergy to birch and apple.
Allergy. 1996 Dec; 51(12):940-5.A

Abstract

Sixty-five patients presenting either rhinoconjunctivitis or asthma and sensitized to pollens of trees of the order Fagales were studied by the Pharmacia CAP system in order to assess specific IgE for the important birch pollen allergens Bet v 1 and Bet v 2. All 65 subjects reacted to at least one of the recombinant birch allergens: 43% to Bet v 1, 30.7% to Bet v 2, and 26% to both. Patients monosensitized to birch did not react to Bet v 2. Of patients with a history of oral allergy syndrome after eating apples, 16/28 (57%) reacted to Bet v 1; among 20 polysensitized subjects presenting oral allergy syndrome after consumption of apple, four reacted to Bet v 2 (20%). Among patients with IgE against both recombinant allergens, six (35.30%) presented symptoms of allergy after eating apples. Our results indicate that sensitization to Bet v 1 is specific for birch and apple allergies, whereas sensitization to Bet v 2 is common in polysensitized patients.

Authors+Show Affiliations

Allergy Unit, S.S. Trinità Hospital, Fossano, Italy.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

9020425

Citation

Rossi, R E., et al. "Evaluation of Recombinant Allergens Bet V 1 and Bet V 2 (profilin) By Pharmacia CAP System in Patients With Pollen-related Allergy to Birch and Apple." Allergy, vol. 51, no. 12, 1996, pp. 940-5.
Rossi RE, Monasterolo G, Operti D, et al. Evaluation of recombinant allergens Bet v 1 and Bet v 2 (profilin) by Pharmacia CAP system in patients with pollen-related allergy to birch and apple. Allergy. 1996;51(12):940-5.
Rossi, R. E., Monasterolo, G., Operti, D., & Corsi, M. (1996). Evaluation of recombinant allergens Bet v 1 and Bet v 2 (profilin) by Pharmacia CAP system in patients with pollen-related allergy to birch and apple. Allergy, 51(12), 940-5.
Rossi RE, et al. Evaluation of Recombinant Allergens Bet V 1 and Bet V 2 (profilin) By Pharmacia CAP System in Patients With Pollen-related Allergy to Birch and Apple. Allergy. 1996;51(12):940-5. PubMed PMID: 9020425.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation of recombinant allergens Bet v 1 and Bet v 2 (profilin) by Pharmacia CAP system in patients with pollen-related allergy to birch and apple. AU - Rossi,R E, AU - Monasterolo,G, AU - Operti,D, AU - Corsi,M, PY - 1996/12/1/pubmed PY - 1996/12/1/medline PY - 1996/12/1/entrez SP - 940 EP - 5 JF - Allergy JO - Allergy VL - 51 IS - 12 N2 - Sixty-five patients presenting either rhinoconjunctivitis or asthma and sensitized to pollens of trees of the order Fagales were studied by the Pharmacia CAP system in order to assess specific IgE for the important birch pollen allergens Bet v 1 and Bet v 2. All 65 subjects reacted to at least one of the recombinant birch allergens: 43% to Bet v 1, 30.7% to Bet v 2, and 26% to both. Patients monosensitized to birch did not react to Bet v 2. Of patients with a history of oral allergy syndrome after eating apples, 16/28 (57%) reacted to Bet v 1; among 20 polysensitized subjects presenting oral allergy syndrome after consumption of apple, four reacted to Bet v 2 (20%). Among patients with IgE against both recombinant allergens, six (35.30%) presented symptoms of allergy after eating apples. Our results indicate that sensitization to Bet v 1 is specific for birch and apple allergies, whereas sensitization to Bet v 2 is common in polysensitized patients. SN - 0105-4538 UR - https://www.unboundmedicine.com/medline/citation/9020425/Evaluation_of_recombinant_allergens_Bet_v_1_and_Bet_v_2__profilin__by_Pharmacia_CAP_system_in_patients_with_pollen_related_allergy_to_birch_and_apple_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0105-4538&date=1996&volume=51&issue=12&spage=940 DB - PRIME DP - Unbound Medicine ER -